<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02138929</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0838</org_study_id>
    <secondary_id>NCI-2014-01455</secondary_id>
    <nct_id>NCT02138929</nct_id>
  </id_info>
  <brief_title>LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma</brief_title>
  <official_title>A Phase I Study of LDE225 in Combination With Everolimus in Patients With Advanced Gastroesophageal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find the highest tolerable dose of LDE225 that&#xD;
      can be given in combination with everolimus to patients with esophageal or GEJ cancer. The&#xD;
      safety of the drug combination will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:&#xD;
&#xD;
      If participant is found to be eligible to take part in this study, participant will be&#xD;
      assigned to a combination dose level of the study drugs based on when participant joins this&#xD;
      study. Up to 6 participants will be enrolled at each dose level. The first group of&#xD;
      participants will receive the lowest dose level of LDE225. Each new group will receive a&#xD;
      higher dose than the group before it, if no intolerable side effects were seen. All&#xD;
      participants will receive the same dose level of everolimus. This will continue until the&#xD;
      highest tolerable combination dose of LDE225 and everolimus is found. Up to 24 participants&#xD;
      will be enrolled in this part of the study.&#xD;
&#xD;
      Once the highest tolerable dose of the combination of LDE225 and everolimus is found, up to&#xD;
      18 participants will receive the combination dose level that was found to be well tolerated&#xD;
      in the earlier part of the study.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      Every study cycle is 28 days.&#xD;
&#xD;
      Participant will take up to 4 capsules or tablets of LDE225 by mouth 1 time every day.&#xD;
      Participant's doctor will tell participant how many capsules/tablets participant will need to&#xD;
      take. Participant should take the study drug each time with a glass of water (about 8 ounces&#xD;
      total) at the same time every day. Participant should swallow the study drug whole, one&#xD;
      capsule/tablet every 2 minutes, without chewing or opening the study drug. Participant should&#xD;
      eat a light breakfast (such as toast and jam) at least 2 hours before taking the study drug,&#xD;
      then participant should not eat or drink anything for at least 1 hour after the dose.&#xD;
&#xD;
      Participant will take up to 2 tablets of everolimus by mouth 1 time every day with the LDE225&#xD;
      capsules without food. Participant will take the tablets each time with a glass of water at&#xD;
      the same time every day. The tablets should be swallowed whole and not chewed or crushed.&#xD;
&#xD;
      If participant cannot swallow the everolimus tablets, the tablets should be dissolved in&#xD;
      water just before taking them. Add about 2 tablespoons of water into a glass. The tablets&#xD;
      should then be added and stirred gently until the tablets are dissolved. This mixture should&#xD;
      then be drunk. Afterwards, the glass should be rinsed with an additional 2 tablespoons of&#xD;
      water and drunk. Participant's doctor will discuss this with participant.&#xD;
&#xD;
      If participant vomits after taking participant's dose of study drugs, participant should not&#xD;
      take another dose that day.&#xD;
&#xD;
      It is very important that participant takes the study drugs given to participant just as the&#xD;
      study doctor tells participant and that participant does not miss any dose. If participant&#xD;
      forgets to take a dose of LDE225, participant should take it as soon as participant remembers&#xD;
      (within 6 hours of the missed dose). If more than 6 hours have passed, participant should&#xD;
      skip that dose and take participant's next dose the next day as planned. If participant&#xD;
      forgets to take a dose of everolimus, participant should skip that dose and take&#xD;
      participant's next dose the next day as planned.&#xD;
&#xD;
      If participant has a study visit that day, participant should take participant's dose of&#xD;
      study drugs at the clinic.&#xD;
&#xD;
      Participant will need to store LDE225 in participant's refrigerator at all times. Everolimus&#xD;
      can be stored at room temperature. Participant should not share participant's supply of&#xD;
      LDE225 and everolimus with anyone. Participant will keep a study drug diary to help&#xD;
      participant keep track of participant's study drug doses. If participant misses or delays a&#xD;
      dose, participant should write it down in the diary. Participant should bring the diary to&#xD;
      every study visit.&#xD;
&#xD;
      At the end of each cycle and when participant stops taking part in the study, participant&#xD;
      will return any leftover study drugs to the study nurse.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      On Day 1 of every cycle:&#xD;
&#xD;
        -  Participant will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2 teaspoons) will be drawn for routine tests.&#xD;
&#xD;
        -  If participant can become pregnant, blood (about 1 teaspoon) or urine will be collected&#xD;
           for a pregnancy test.&#xD;
&#xD;
      Every week during Cycle 1 only, the study staff will call and ask participant how participant&#xD;
      is doing.&#xD;
&#xD;
      On Day 1 of Cycle 2 and every 2 cycles after that, participant will have an EKG.&#xD;
&#xD;
      On Day 1 of Cycle 3 and every 2 cycles after that, participant will have a CT scan or MRI of&#xD;
      the chest, abdomen, and pelvis to check the status of the disease.&#xD;
&#xD;
      If the doctor thinks it is needed, extra blood may be drawn to follow up on any side effects.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      Participant may continue taking the study drugs for as long as the doctor thinks it is in&#xD;
      participant's best interest. Participant will no longer be able to take the study drugs if&#xD;
      the disease gets worse, if intolerable side effects occur, or if participant is unable to&#xD;
      follow study directions.&#xD;
&#xD;
      Participation on the study will be over after the follow-up visit (described below).&#xD;
&#xD;
      End-of-Study Visit:&#xD;
&#xD;
      Within 14 days after participant's last dose of study drugs:&#xD;
&#xD;
        -  Participant will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2 tablespoons) will be drawn for routine tests, to check the cholesterol&#xD;
           levels in participant's blood, and to check how well participant's blood clots.&#xD;
           Participant will need to fast for at least 8 hours before this blood draw.&#xD;
&#xD;
        -  Participant will have an EKG.&#xD;
&#xD;
        -  Participant will have a CT scan or MRI of the chest, abdomen, and pelvis to check the&#xD;
           status of the disease, if the doctor thinks it is needed.&#xD;
&#xD;
        -  If participant can become pregnant, blood (about 1 teaspoon) or urine will be collected&#xD;
           for a pregnancy test.&#xD;
&#xD;
      Follow-Up Visit:&#xD;
&#xD;
      At 30 days after the end-of-study visit:&#xD;
&#xD;
        -  Participant will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2 tablespoons) will be drawn for routine tests.&#xD;
&#xD;
        -  Participant will have an EKG.&#xD;
&#xD;
        -  If participant can become pregnant, blood (about 1 teaspoon) or urine will be collected&#xD;
           for a pregnancy test.&#xD;
&#xD;
      About 3 months after the follow-up visit, participant will be contacted by the study staff by&#xD;
      telephone and/or seen in the clinic. Participant will be asked about any drugs participant&#xD;
      may be taking and about participant's general health. If participant is called, the call will&#xD;
      take about 5-10 minutes.&#xD;
&#xD;
      This is an investigational study. LDE225 is not FDA approved or commercially available.&#xD;
      Everolimus is FDA approved and commercially available to treat kidney, breast, and pancreatic&#xD;
      cancers. The combination of LDE225 and everolimus to treat esophageal or GEJ cancer is&#xD;
      investigational.&#xD;
&#xD;
      The study doctor can explain how the study drugs are designed to work.&#xD;
&#xD;
      Up to 42 participants will be enrolled in this study. All will take part at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 10, 2014</start_date>
  <completion_date type="Actual">June 8, 2020</completion_date>
  <primary_completion_date type="Actual">June 8, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of LDE225 in Combination with Everolimus in Participants with Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction (GEJ) or Stomach in the Second or Third Line Setting</measure>
    <time_frame>10 weeks</time_frame>
    <description>Maximum tolerated dose (MTD) defined as highest dose level for the combination therapy with no more than 1 out of 6 patients experiencing dose limiting toxicity (DLT). DLT defined as an adverse event (AE) or abnormal laboratory value assessed as at least possibly related to the study medication, occurs â‰¤56 days following the first dose of LDE225 (DLT assessment period).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of LDE225 in Combination with Everolimus in a Cohort of Participants with Metastatic Nuclear Gli-1 Expressing Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach per CTCAE.</measure>
    <time_frame>30 days after last dose of study drug given.</time_frame>
    <description>A Bayesian method by Thall, Simon, and Estey [37] used for safety monitoring, starting from the 5th patient. The monitoring rule for toxicity is Pr (P(Tox) &gt; 0.25 | data) &gt; 0.80, where P(Tox) is the proportion of patients that experience DLT and it has a prior distribution of beta (0.5, 1.5).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Everolimus + LDE 225</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: Everolimus at a dose of 10 mg by mouth daily with dose escalation of LDE 225 from 200 mg - 800mg by mouth daily. Study cycle is 28 days.&#xD;
Dose Expansion: Everolimus at a dose of 10 mg by mouth daily. LDE 225 at MTD from Dose Escalation. Study cycle is 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.</description>
    <arm_group_label>Everolimus + LDE 225</arm_group_label>
    <other_name>Afinitor</other_name>
    <other_name>Zortress</other_name>
    <other_name>RAD001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDE 225</intervention_name>
    <description>Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.&#xD;
Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase.</description>
    <arm_group_label>Everolimus + LDE 225</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have histologically or cytologically confirmed adenocarcinoma of&#xD;
             esophagus,gastroesophageal junction, or stomach which is Gli-1 positive (labeling&#xD;
             index [LI] greater than or equal to 5%). Testing is to be performed in a CLIA&#xD;
             certified laboratory. The patients must have an archival tumor sample to facilitate&#xD;
             this testing.&#xD;
&#xD;
          2. Patients must have an unresectable locally advanced or metastatic adenocarcinoma.&#xD;
&#xD;
          3. Patients agreeing to the optional biomarker study in the expansion phase only need to&#xD;
             have an accessible primary tumor. (Optional biomarker studies will be done in up to 18&#xD;
             patients in the expansion phase only.)&#xD;
&#xD;
          4. Patient must have received at least one, and no more than two prior systemic therapies&#xD;
             for metastatic cancer.&#xD;
&#xD;
          5. Patients whose esophageal or GEJ cancer has become metastatic or unresectable locally&#xD;
             advanced within 6 months of completing definitive therapy for localized or locally&#xD;
             advanced cancer can be considered as having received one line of therapy for advanced&#xD;
             cancer.&#xD;
&#xD;
          6. Patients must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded for&#xD;
             non-nodal lesions and short axis for nodal lesions) as greater than 20 mm with&#xD;
             conventional techniques or as greater than 10 mm with spiral CT scan.&#xD;
&#xD;
          7. Male or female patients greater than or equal to 18 years old.&#xD;
&#xD;
          8. ECOG performance status less than 2.&#xD;
&#xD;
          9. Patients must have normal organ and marrow function as defined below: leukocytes&#xD;
             greater than 3,000/mcL; absolute neutrophil count greater than1,500/mcL; platelets&#xD;
             greater than 100,000/mcL; Hemoglobin (Hgb) greater than or equal to 9 g/dL&#xD;
             (transfusions are allowed); total bilirubin within normal institutional limits;&#xD;
             AST(SGOT)/ALT(SGPT) less than 2.5 x institutional upper limit of normal (ULN) or less&#xD;
             than or equal to 5 x institutional ULN if liver metastasis are present; Serum&#xD;
             creatinine less than or equal to 1.5 x ULN or 24-hour clearance greater than or equal&#xD;
             to 50ml/min; Plasma creatine phosphokinase (CK) less than 1.5 x ULN; INR less than or&#xD;
             equal to 2; Fasting serum cholesterol less than or equal to 300 mg/dL OR less than or&#xD;
             equal to 7.75 mmol/L AND fasting triglycerides less than or equal to 2.5 x ULN.&#xD;
&#xD;
         10. Patient should be able to swallow and retain oral medications.&#xD;
&#xD;
         11. Women of childbearing potential and men must use two forms of contraception&#xD;
             (non-hormonal or barrier method of birth control; abstinence) prior to study entry and&#xD;
             for the duration of study participation and for 6 months after the final dose of study&#xD;
             treatment.&#xD;
&#xD;
         12. Ability to understand and the willingness to sign a written informed consent document.&#xD;
             Signed informed consent will be obtained prior to any screening procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients currently receiving anticancer therapies or who have received anticancer&#xD;
             therapies within 4 weeks of the start of Everolimus and LDE225 (including&#xD;
             chemotherapy, radiation therapy, antibody based therapy, etc.).&#xD;
&#xD;
          2. Uncontrolled diabetes mellitus as defined by HbA1c greater than 8% despite adequate&#xD;
             therapy. Patients with a known history of impaired fasting glucose or diabetes&#xD;
             mellitus (DM) may be included, however blood glucose and antidiabetic treatment must&#xD;
             be monitored closely throughout the trial and adjusted as necessary.&#xD;
&#xD;
          3. Patients who have any severe and/or uncontrolled medical conditions such as: a)&#xD;
             unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction&#xD;
             less than or equal to 6 months prior to start of Everolimus, serious uncontrolled&#xD;
             cardiac arrhythmia, or any other clinically significant cardiac disease; b)&#xD;
             symptomatic congestive heart failure of New York Heart Association Class III or IV; c)&#xD;
             active (acute or chronic) or uncontrolled severe infection, liver disease such as&#xD;
             cirrhosis, decompensated liver disease, and chronic hepatitis (i.e. quantifiable&#xD;
             HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA); d) known severely impaired lung&#xD;
             function (spirometry and DLCO 50% or less of normal and O2 saturation 88% or less at&#xD;
             rest on room air); e) active, bleeding diathesis.&#xD;
&#xD;
          4. Patients who have a history of another primary malignancy, with the exceptions of:&#xD;
             non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from&#xD;
             which the patient has been disease free for greater than or equal to 3 years.&#xD;
&#xD;
          5. Patients with a history of non-compliance to medical regimens or who are considered&#xD;
             potentially unreliable or will not be able to complete the entire study.&#xD;
&#xD;
          6. Pregnant or nursing (lactating) women.&#xD;
&#xD;
          7. Women of child-bearing potential (WOCBP), defined as all women physiologically capable&#xD;
             of becoming pregnant, must use highly effective methods of contraception during the&#xD;
             study and 6 months after. Hormonal contraception methods (e.g. oral, injected,&#xD;
             implanted) are not allowed as it cannot be ruled out that the study drug decreases the&#xD;
             effectiveness of hormonal contraception. Highly effective contraception methods&#xD;
             include combination of any two of the following: a) Placement of a non-hormonal&#xD;
             intrauterine device (IUD) or non-hormonal intrauterine system (IUS); b) Barrier&#xD;
             methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps)&#xD;
             with spermicidal foam/gel/film/cream/ vaginal suppository; c. Total abstinence (When&#xD;
             this is in line with the preferred and usual lifestyle of the patient. Periodic&#xD;
             abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and&#xD;
             withdrawal are not acceptable methods of contraception.);&#xD;
&#xD;
          8. (Continued from # 7): or d) Male/female sterilization. (Sterilization: Patient has had&#xD;
             surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at&#xD;
             least six weeks before taking study treatment. In case of oophorectomy alone, only&#xD;
             when the reproductive status of the woman has been confirmed by follow up hormone&#xD;
             level assessment. Male partner sterilization (with the appropriate post-vasectomy&#xD;
             documentation of the absence of sperm in the ejaculate). [For female study patients,&#xD;
             the vasectomized male partner should be the sole partner for that patient.]).&#xD;
&#xD;
          9. (Continued from # 8): Women are considered post-menopausal and not of child-bearing&#xD;
             potential if they have had 12 months of natural (spontaneous) amenorrhea with an&#xD;
             appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or&#xD;
             have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal&#xD;
             ligation at least six weeks prior to randomization. In the case of oophorectomy alone,&#xD;
             only when the reproductive status of the woman has been confirmed by follow up hormone&#xD;
             level assessment is she considered not of child-bearing potential.&#xD;
&#xD;
         10. Male patients whose sexual partner(s) are WOCBP who are not willing to use adequate&#xD;
             contraception, during the study and for 6 months after the end of treatment (Male&#xD;
             patients must use highly effective (double barrier) methods of contraception (e.g.,&#xD;
             spermicidal gel plus condom) for the entire duration of the study, and continuing&#xD;
             using contraception and refrain from fathering a child for 6 months following the&#xD;
             study drug. A condom is required to be used also by vasectomized men as well as during&#xD;
             intercourse with a male partner in order to prevent delivery of the study treatment&#xD;
             via seminal fluid.).&#xD;
&#xD;
         11. Patients with known brain metastases should be excluded from this clinical trial&#xD;
             because of their poor prognosis and because they often develop progressive neurologic&#xD;
             dysfunction that would confound the evaluation of neurologic and other adverse events.&#xD;
&#xD;
         12. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to LDE 225 or Everolimus in the study or other rapamycin analogs (e.g.&#xD;
             sirolimus, temsirolimus).&#xD;
&#xD;
         13. Patients who are receiving treatment with medications known to be moderate and strong&#xD;
             inhibitors or inducers of CYP3A4/5 or drugs metabolized by CYP2B6 or CYP2C9 that have&#xD;
             narrow therapeutic index, and that cannot be discontinued before starting treatment&#xD;
             with LDE225. Medications that are strong CYP3A4/5 inhibitors should be discontinued at&#xD;
             least 7 days and strong CYP3A/5 inducers for at least 2 weeks prior to starting&#xD;
             treatment with LDE225.&#xD;
&#xD;
         14. Patients receiving any medications or substances that are inhibitors or inducers of&#xD;
             CYP 450 3A4 are ineligible.&#xD;
&#xD;
         15. Patients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular&#xD;
             dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on&#xD;
             concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as&#xD;
             HMG CoA inhibitors (statins), clofibrate and gemfibrozil, and that cannot be&#xD;
             discontinued at least 2 weeks prior to starting LDE225 treatment. Patients who are&#xD;
             planning on embarking on a new strenuous exercise regimen after initiation of study&#xD;
             treatment, should also be excluded. Muscular activities, such as strenuous exercise,&#xD;
             that can result in significant increases in plasma CK levels should be avoided whilst&#xD;
             on LDE225 treatment.&#xD;
&#xD;
         16. Concurrent medical condition requiring the use of immunosuppressive medications or&#xD;
             immunosuppressive doses of systemic or absorbable topical corticosteroids (doses&#xD;
             greater than 10mg/day prednisone or equivalent). Inhaled or intranasal corticosteroids&#xD;
             (with minimal systemic absorption) may be continued. Non-absorbed intra-articular&#xD;
             steroid injections are allowed. The exception to the use of steroids is the treatment&#xD;
             of serious adverse events (SAEs) such as pneumonitis and the prevention of emesis.&#xD;
&#xD;
         17. Known history of HIV seropositivity.&#xD;
&#xD;
         18. Patients who have received live attenuated vaccines within 1 week of start of&#xD;
             Everolimus and during the study.&#xD;
&#xD;
         19. Impaired cardiac function or clinically significant heart disease, including any one&#xD;
             of the following: a) Angina pectoris within 3 months; b) Acute myocardial infarction&#xD;
             within 3 months; c) QTcF greater than 450 msec for males and greater than 470 msec for&#xD;
             females on the screening electrocardiogram (ECG); d) A past medical history of&#xD;
             clinically significant ECG abnormalities or a family history of prolonged QT-interval&#xD;
             syndrome; e) Other clinically significant heart disease (e.g. congestive heart&#xD;
             failure, uncontrolled hypertension, history of labile hypertension, or history of poor&#xD;
             compliance with an antihypertensive regimen).&#xD;
&#xD;
         20. All patients known to be positive for hepatitis B will be excluded from the study, and&#xD;
             those at high risk for hepatitis B infection will be screened.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaffer Ajani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Advanced adenocarcinoma of the esophagus</keyword>
  <keyword>Advanced adenocarcinoma of the gastroesophageal junction</keyword>
  <keyword>GEJ</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Afinitor</keyword>
  <keyword>Zortress</keyword>
  <keyword>RAD001</keyword>
  <keyword>LDE 225</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

